Article Text

Download PDFPDF
Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease
  1. A Colzi,
  2. K Turner,
  3. A J Lees
  1. Department of Neurological Sciences, Middlesex Hospital, Mortimer Street, London, UK
  1. Dr A.J. Lees, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG.

Abstract

OBJECTIVES To determine whether continous waking day dopaminergic stimulation with the dopamine agonist apomorphine can reduce levodopa induced dyskinesias in Parkinson’s disease

METHODS 19 patients with severe unpredictable refractory motor fluctuations and functionally disabling levodopa induced dyskinesias were treated with continuous subcutaneoius apomorphine monotherapy for a minimum duration of 2.7 years

RESULTS A mean 65% reduction in dyskinetic severity and a mean 85% reduction in frequency and duration occurred. On discontinuing levodopa a concomitant reduction in off period time was also seen (35% of waking day “off” reduced to 10%)

CONCLUSION Continuous waking day dopaminergic stimulation with apomorphine reset the threshold for dyskinesias and led to a pronounced reduction in their frequency. Apomorphine should be considered as a less invasive alternative to pallidotomy or deep cerebral stimulation in controlling levodopa induced interdose dose dyskinesias.

  • apomorphine
  • Parkinson’s disease
  • levodopa induced dyskinesias
  • continuous drug delivery

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes